Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Qingdao Port Cardiovascular Health Study: a prospective cohort study.

BMJ open·2015
Same author

Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement: Report From the STS/ACC TVT Registry.

Circulation. Cardiovascular interventions·2015
Same author

Screening Health Questionnaires and Patient-Reported Outcomes: Will Shortened Versions Overcome the Barriers to Their Implementation.

Journal of cardiac failure·2015
Same author

Variation of Quality of Life Data Collection Across INTERMACS Sites.

Journal of cardiac failure·2015
Same author

Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.

The New England journal of medicine·2015
Same author

Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention.

JAMA·2015

Related Experiment Video

Updated: Sep 9, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction.

Mohammad Abdel Jawad1,2, John A Spertus1,2, Yoon J Cho1,2

  • 1University of Missouri Kansas City's Healthcare Institute for Innovations in Quality, Kansas City.

JAMA Network Open
|August 28, 2025
PubMed
Summary

Beta-blocker use in heart failure with preserved ejection fraction (HFpEF) did not significantly impact patient health status. This study found no association between beta-blockers and baseline health status or spironolactone

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

213

Related Experiment Videos

Last Updated: Sep 9, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

213

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Pharmacology

Background:

  • Beta-blockers are commonly prescribed for heart failure with preserved ejection fraction (HFpEF).
  • The impact of beta-blockers on health status in HFpEF patients is not well-established.

Purpose of the Study:

  • To investigate the association between beta-blocker use and health status in patients with HFpEF.
  • To determine if beta-blockers modify the health status benefits of spironolactone in HFpEF.

Main Methods:

  • Secondary analysis of a randomized clinical trial involving 1726 HFpEF patients.
  • Health status assessed using the Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS).
  • Multivariable linear regression used to analyze cross-sectional and longitudinal associations, with interaction testing for LVEF and spironolactone.

Main Results:

  • Beta-blocker use was not significantly associated with baseline KCCQ-OS scores (mean difference: -1.1 points; P=.38).
  • No significant interaction was found between beta-blocker use and LVEF regarding health status.
  • Beta-blockers did not significantly modify the health status benefits of spironolactone at 4 months (P=.20 for interaction).

Conclusions:

  • Beta-blocker therapy in HFpEF patients is not associated with significant changes in health status.
  • Further research is warranted to fully elucidate the role of beta-blockers in HFpEF management and patient outcomes.